Stat1-Deficient Mice Are Not an Appropriate Model for Efficacy Testing of Recombinant Vesicular Stomatitis Virus-Based Filovirus Vaccines

Journal of Infectious Diseases

Volumn 212, Issue , 2015, Pages S404-S409

  Marzi, Andrea ^a   Kercher, Lisa ^b   Marceau, Joshua ^a,c   York, Anthony ^a   Callsion, Julie ^a   Gardner, Donald J ^b   Geisbert, Thomas W ^d,e   Feldmann, Heinz ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b National Institute   (New Zealand)

^c UNIVERSITY OF MONTANA   (United States)

^d Department of Pathology   (United States)

^e University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Ebolavirus; Marburgvirus; Stat1 deficient mice; vaccine; Vesicular stomatitis virus

Indexed keywords

FILOVIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT VESICULAR STOMATITIS VIRUS VECTOR; STAT1 PROTEIN; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR; LIVE VACCINE; STAT1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; EBOLA HEMORRHAGIC FEVER; MARBURG HEMORRHAGIC FEVER; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; VIRAL TROPISM; VIRUS LOAD; ANIMAL; CHLOROCEBUS AETHIOPS; DEFICIENCY; DISEASE MODEL; EBOLAVIRUS; FILOVIRIDAE; FILOVIRUS INFECTION; GENE VECTOR; GENETICS; IMMUNOLOGY; MARBURGVIRUS; VERO CELL LINE; VESICULAR STOMATITIS; VIROLOGY; VIRUS REPLICATION;

ANIMALS; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; EBOLAVIRUS; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; GENETIC VECTORS; HEMORRHAGIC FEVER, EBOLA; MARBURG VIRUS DISEASE; MARBURGVIRUS; MICE; STAT1 TRANSCRIPTION FACTOR; VACCINES, ATTENUATED; VERO CELLS; VESICULAR STOMATITIS; VIRAL LOAD; VIRAL VACCINES; VIRUS REPLICATION;

EID: 84943265613     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv188     Document Type: Article

References (14)

1. Feldmann H, Sanchez A, Geisbert TW. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, eds. Fields virology. Philadelphia: Lippincott Williams and Wilkins, 2013:923-56.
2. World Health Organization. Ebola situation report, 11 March 2015. Geneva, Switzerland: WHO, 2015.
3. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786-90.
4. Marzi A, Feldmann H, Geisbert TW, Falzarano D. Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections. J Bioterror Biodef 2011; doi:10.4172/2157-2526.S1-004.
5. Bray M. The role of the Type I interferon response in the resistance of mice to filovirus infection. J Gen Virol 2001; 82:1365-73.
6. Raymond J, Bradfute S, Bray M. Filovirus infection of STAT-1 knockout mice. J Infect Dis 2011; 204(suppl 3):S986-90.
7. Jones SM, Stroher U, Fernando L, et al. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 2007; 196(suppl 2):S404-12.
8. Katzenell S, Chen Y, Parker ZM, Leib DA. The differential interferon responses of two strains of Stat1-deficient mice do not alter susceptibility to HSV-1 and VSV in vivo. Virology 2014; 450-451:350-4.
9. Lawson ND, Stillman EA,WhittMA, Rose JK. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A 1995; 92:4477-81.
10. Garbutt M, Liebscher R,Wahl-Jensen V, et al. Properties of replicationcompetent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004; 78:5458-65.
11. Marzi A, Ebihara H, Callison J, et al. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis 2011; 204(suppl 3):S1066-74.
12. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27:493-7.
13. Mire CE, Geisbert JB, Agans KN, et al. Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates. PLoS One 2014; 9:e94355.
14. Honke N, Shaabani N, Cadeddu G, et al. Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat Immunol 2012; 13:51-7.